secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2023-12-21T23:59:59+00:00
Accession:  0001193125-23-300388
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck reports early efficacy for SL-172154 in frontline HR-MDS and TP53m AML
-------------------------------------------------------------------------------

- HR-MDS: 5/14 evaluable patients achieved CR; 4 achieved mCR with hematologic improvement.
- TP53m AML: 2/11 evaluable patients achieved CR; 1 patient with CRi proceeded to allo-HCT.
- Grade 3/4 AEs related to SL-172154 reported in 14% of TP53m AML and 18% of HR-MDS patients.
- Infusion-related reactions most common TEAE; no destructive anemia observed.
- Cohorts expanded; additional data expected mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000119312523300388/0001193125-23-300388-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000119312523300388/d14784d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-300388

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer